Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for patients with chronic lymphocytic leukemia (CLL), despite extensive heterogeneity in this disease. To define the underlining regulatory dynamics, we analyze high-resolution time courses of ibrutinib treatment in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rendeiro, André F., Krausgruber, Thomas, Fortelny, Nikolaus, Zhao, Fangwen, Penz, Thomas, Farlik, Matthias, Schuster, Linda C., Nemc, Amelie, Tasnády, Szabolcs, Réti, Marienn, Mátrai, Zoltán, Alpár, Donát, Bödör, Csaba, Schmidl, Christian, Bock, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989523/
https://www.ncbi.nlm.nih.gov/pubmed/31996669
http://dx.doi.org/10.1038/s41467-019-14081-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989523/
https://www.ncbi.nlm.nih.gov/pubmed/31996669
http://dx.doi.org/10.1038/s41467-019-14081-6

Ejemplares similares